Yttrium-90–ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma

Long-term follow-up of 90Y-ibritumomab-tiuxetan (90YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center

“…These data confirm the safety of Z-BEAM conditioning regimen in this setting and correlate with the low risk of therapy-related malignancies already mentioned after RIT. 13 Overall response rate is 100% in our Z-BEAM group like that shown in prospective studies 8,9,11 and in GELA's study including 87% of FLs 6 ( Table 2). After a median follow-up of 52.7 months (range 2.4-86.6 months), 10 patients relapsed (71%) in the Z-BEAM group.…”

“…6,8,9,11 Time to absolute neutrophil count recovery was 12 days vs 10.5 day (P = 0.069) and time to platelet recovery was 12 vs 13 days (P = 0.45). One patient in the Z-BEAM group had a prolonged aplasia despite a transfused CD34 + cells count 44 × 10 6 /kg.…”

“…Briefly, PBSC were collected by apheresis after mobilization with SC hematopoietic growth factor support as already described. 8,9 The transfused graft had to contain more than 4 × 10 6 CD34 + cells/kg to be included in our study. In Z-BEAM regimen, Rituximab (F. Hoffmann-La Roche, Basel, Switzerland) was first injected in purpose to promptly saturate all natural nontumoral antigenic site before the radionucleotid infusion.…”

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

“…In a phase II study of 23 patients with chemo-refractory lymphoma, we used standard-dose Zevalin with high-dose BEAM chemotherapy prior to autologous SCT. 21 The estimated 2-year progression-free survival was 52%, a promising outcome for patients in this setting. Although we could not rule out an increase in NRM, relapse rates were markedly less than expected, translating into improved PFS.…”

“…17 The initial studies using radioimmunotherapy in combination with high-dose chemotherapy and autologous SCT show promising results. [18][19][20][21][22] In this study, we explored the use of standard-dose Zevalin combined with RIC and allogeneic SCT in patients with chemorefractory lymphoma expected to have poor outcome with standard SCT.…”